Tempus and JW Pharmaceutical Partner on AI-Driven Oncology Research
Slice of Healthcare Team
10/30/2024
Key Highlights
- Tempus partners with JW Pharmaceutical to advance AI-driven cancer research.
- Utilizes real-world data (RWD) and biological modeling in early-stage oncology research.
- Patient-derived organoid models aid in biomarker discovery and asset prioritization.
- Collaboration aligns with global trends in data-driven drug development.
- Expected to enhance Korea’s domestic drug development landscape.
Source: Business Wire
Notable Quotes
“ We are excited to work with a forward-looking collaborator like JW Pharmaceutical, a pioneer in Korea that is embracing the power of RWD and AI to advance the next generation of cancer therapeutics. ”
Ryan Fukushima, COO at Tempus
“ This collaboration marks a turning point in data-driven drug development using RWD in Korea, aligning with global trends and expected to positively impact the domestic drug development landscape. ”
Chan-Hee Park, CTO at JW Pharmaceutical
